Table 2.
Distribution of ASMs in responders group and non-responders group (n = 486).
| Epilepsy treatment regimen | Responders group (N = 108) | Non-responders group (N = 378) |
|---|---|---|
| Mono-therapy | 56 (51.85) | 80 (21.16) |
| bi-therapy | 33 (30.56) | 136 (35.98) |
| Poly-therapy | 19 (17.59) | 162 (42.86) |
| Anti-seizures medication profile: Fist generation anti-seizure medications | ||
| • PHT (130) | 32 (24.62) | 98 (75.38) |
| • CBZ (168) | 31 (18.45) | 137 (81.55) |
| • VPA (251) | 41 (16.33) | 210 (83.67) |
| • PHB (14) | 2 (14.29) | 12 (85.71) |
| Newer medications: | ||
| • CLB (195) | 28 (14.36) | 167 (85.64) |
| • LEV (151) | 22 (14.57) | 129 (85.43) |
| • CLNZ (26) | 8 (30.77) | 18 (69.23) |
| • LTG (48) | 8 (16.67) | 40 (83.33) |
| • ZNS (24) | 3 (12.50) | 21 (87.50) |
| • TPM (28) | 3 (10.71) | 25 (89.29) |
| • OxCBZ (31) | 5 (16.13) | 26 (83.87) |
| • PGB (1) | 0 (0.0) | 1 (100) |
| • GBP (1) | 0 (0.0) | 1 (100) |
| Medications Doses (mg/day) First generation anti-seizure medications | ||
| • PHT | 272.65 ± 75.49 | 261.6327 114.07 |
| • CBZ | 633.87 ± 254.09 | 758.03 ± 295.19 |
| • VPA | 925.61 ± 349.48 | 987.1429 388.01 |
| • PHB | 37.5 ± 31.81 | 87.08 ± 49.28 |
| Newer medications | ||
| • CLB | 11.10 ± 4.97 | 15.11 ± 6.98 |
| • LEV | 1931.81 ± 707.87 | 2140.31 ± 934.51 |
| • CLNZ | 1 ± 1.26 | 0.53 ± 0.29 |
| • LTG | 131.25 ± 81.00 | 199.825 ± 184.43 |
| • ZNS | 250 ± 50 | 488.09 ± 398.40 |
| • TPM | 233.33 ± 152.75 | 160 ± 86.60 |
| • OxCBZ | 870 ± 268.32 | 1050 ± 384.44 |
| • PGB | 0 | 600 |
| • GBP | 0 | 225 |
(Data are represented as number (percentage), PHT = phenytoin, CBZ = carbamazepine, VPA = valproic acid, PHB = phenobarbitol,CLB = Clabazam, LEV = levetiractam, CLNZ = Clonazepam, LTG = lamotrigine, ZNS = Zonisamide, TPM = Topiramate, Ox-CBZ = Oxcarbamazepine, PGB = pregablin, GBP = gabapentin).